| Literature DB >> 26528497 |
Kazuya Akahoshi1, Yasuaki Motomura1, Masaru Kubokawa1, Junya Gibo1, Nobukatsu Kinoshita1, Shigeki Osada1, Kayo Tokumaru1, Taizou Hosokawa1, Naru Tomoeda1, Yoshihiro Otsuka1, Mie Matsuo1, Masafumi Oya2, Hidenobu Koga3, Kazuhiko Nakamura4.
Abstract
BACKGROUND AND STUDY AIMS: The Clutch Cutter (CC) was developed to reduce the risk of complications related to endoscopic submucosal dissection (ESD) using knives. The CC is able to grasp and coagulate and/or incise the targeted tissue using electrosurgical current, like a biopsy technique. The aim of this study was to evaluate the efficacy and safety of ESD using the CC (ESD-CC) for early gastric cancer (EGC). PATIENTS AND METHODS: From June 2007 to March 2014, 325 consecutive patients with a diagnosis of EGC were enrolled in this prospective study. They had all satisfied the Japanese gastric cancer treatment guidelines for ESD indication, namely confirmation by preliminary endoscopy, endoscopic ultrasound, and endoscopic biopsies. The CC was used for all steps of ESD (marking, circumferential marginal incision, submucosal dissection, and hemostatic treatment). The therapeutic efficacy and safety were assessed.Entities:
Year: 2015 PMID: 26528497 PMCID: PMC4612246 DOI: 10.1055/s-0034-1392509
Source DB: PubMed Journal: Endosc Int Open ISSN: 2196-9736
JGCA indication criteria for ESD for early gastric cancer.
|
|
| Tumor size < 2 cm, histologically of differentiated type, |
| T1a, ulcer (–) |
|
|
| (a) Tumor size > 2 cm, histologically of differentiated type, |
| T1a, ulcer (–) |
| (b) Tumor size < 3 cm, histologically of differentiated type, |
| T1a, ulcer ( + ) |
| (c) Tumor size < 2 cm, histologically of undifferentiated type, |
| T1a, ulcer (–) |
|
|
| Not satisfying any of the above criteria |
Fig. 1Distal tip of the Clutch Cutter. The serrated jaw provides accurate targeting (grasping). The outer side of the forceps is insulated so that electrosurgical current energy is concentrated at the blade, which prevents burning of the surrounding tissue.
Fig. 2Endoscopic view of the ESD procedure using the CC. a Chromoendoscopy with indigo carmine to demarcate the lesion. b Marks are made at several points along the outline of the lesion with a coagulation current. c The mucosa is incised outside the marker dots to separate the lesion from the surrounding non-neoplastic mucosa using the CC. d The submucosal connective tissue immediately beneath the lesion is gradually dissected from the muscle layer using the CC. e The lesion is cut completely from the muscle layer. f The resected specimen shows en-bloc resection of the lesion.
Fig. 3Basic technique of the Clutch Cutter ESD. Step 1 (Accurate targetting): The target tissue is accurately grasped by the CC. Step 2 (Leaving from the proper muscle layer): The grasped tissue is pulled (or lifted up) to avoid electrical damage to the proper muscle layer. Step 3 (Pre-cut coagulation): The grasped tissue including the blood vessel is coagulated for prevention of intraoperative bleeding. Step 4 (Cut): The grasped tissue is cut using electrosurgical current for the incision. Arrow: Direction of pull, m: mucosa, sm: submucosa, mp: muscularis propria, has: hyaluronic acid solution, bv: blood vessel.
Clinicopathological characteristics (N = 325).
| Sex, male/female | 228/97 |
| Mean ± SD (range) age (years) | 73.7 ± 9.0 (35 – 95) |
| Histologic type (%) | |
| Differentiated type adenocarcinoma | 315 (97 %) |
| Undifferentiated type adenocarcinoma | 10 (3 %) |
| Location (%) | |
| Lower | 131 (40 %) |
| Middle | 99 (31 %) |
| Upper | 95 (29 %) |
| Indication criteria for ESD | |
| Absolute indication group | 204 (63 %) |
| Expanded indication group | 83 (25 %) |
| Exclusion indication group | 38 (12 %) |
Technical results of ESD with the Clutch Cutter (N = 325).
| Mean ± SD size of lesion, mm (range) | 17.3 ± 12.1 (2 – 74) |
| Mean ± SD size of resected specimen, mm (Range) | 46.7 ± 15.5 (18 – 95) |
| En-bloc resection rate (%) | 324/325 (99.7 %) |
| R0 resection rate (%) | 310/325 (95.3 %) |
| Complication rate | 12/325 (3.6 %) |
| Intraoperative perforation rate | 1/325 (0.3 %) |
| Intraoperative uncontrollable bleeding rate | 0/325 (0 %) |
| Postoperative perforation rate | 0/325 (0 %) |
| Postoperative bleeding rate | 11/325 (3.4 %) |
R0 resection rate and operating time for ESD using the Clutch Cutter according to clinicopathological factors (N = 325).
|
| |
| Tumor size | |
| 0 – 20 mm | 230/235 (97.9 %) |
| 21-mm | 80/90 (88.9 %) |
| |
|
| Histologic type | |
| Differentiated type adenocarcinoma | 301/315 (95.6 %) |
| Undifferentiated type adenocarcinoma | 9/10 (90 %) |
| | NS |
| Location | |
| Lower | 127/131 (96.9 %) |
| Middle | 91/99 (91.9 %) |
| Upper | 92/95 (96.8 %) |
| | NS |
| Indication criteria | |
| Absolute indication group | 201/204 (98.5 %) |
| Expanded indication group | 81/83 (97.6 %) |
| Exclusion indication group | 28/38 (73.7 %) |
| |
|
|
| |
| Tumor size | |
| 0 – 20 mm | 82.4 ± 58.8 (14 – 423) |
| 21-mm | 135.4 ± 63.2 (20 – 340) |
| |
|
| Histologic type | |
| Differentiated type adenocarcinoma | 95.5 ± 62.3 (14 – 379) |
| Undifferentiated type adenocarcinoma | 149 ± 106.4 (51 – 423) |
| |
|
| Location | |
| Lower | 73.9 ± 44.9 (15 – 230) |
| Middle | 108.8 ± 58.8 (19 – 300) |
| Upper | 117.2 ± 81.6 (14 – 423) |
| |
|
| Indication criteria | |
| Absolute indication group | 78.8 ± 54.7 (14 – 379) |
| Expanded indication group | 128.7 ± 68.0 (33 – 423) |
| Exclusion indication group | 126.3 ± 68.9 (20 – 340) |
| |
|
Fig. 4Learning curve of (◆) operating time, (■) R0 resection rate, and (▲) perforation rate.